Longitudinal Study of Patients with Connective Tissue Disease-Interstitial Lung Disease and Response to Mycophenolate Mofetil and Rituximab.

To investigate the effect of mycophenolate mofetil (MMF) and rituximab (RTX) on pulmonary function test (PFT) results in a mixed cohort of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD), longitudinally followed up for 1 year in a single academic center. Patients with CTD-ILD were identified in electronic medical records from 1 January 2009 to 30 April 2019. Prescribed MMF and RTX doses, dosage changes, and therapy plans were analyzed individually with improvement in PFT outcomes determined using multivariable linear regression models during 12-month follow-up.

Targeting HIF-2α: the role of belzutifan in clear cell renal carcinoma management.

Introduction: Belzutifan is a first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. It targets the von Hippel-Lindau protein (pVHL)-HIF-vascular endothelial growth factor (VEGF) pathway, which is crucial in cellular responses to hypoxia. By inhibiting HIF-2α, belzutifan disrupts the transcription of genes involved in tumor growth and angiogenesis.

Human development and entrepreneurship: A cross-country analysis of early-stage, intention, and discontinuation.

Entrepreneurship is widely recognized as a vital driver of economic growth, yet its relationship through different stages with broader, non-purely monetary dimensions still needs to be explored. This research seeks to fill this gap by investigating the association between human development and entrepreneurship, recognizing the crucial role of environmental conditions in shaping entrepreneurial activity. Our cross-country Bayesian analysis shows strong evidence that a nation's level of human development is associated with entrepreneurial activity in three stages: early entrepreneurship, intention for future engagement, and discontinuation of ventures.